---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000030"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:06:51.028867+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M

## Summary
- Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
- Revenue fell to $12.8M from $19.0M; non-cash royalty revenue vs prior milestone revenue.
- Cash and marketable securities $646.7M at March 31, down from $697.4M at year-end 2023.
- First patient dosed in Phase 1 for XmAb541 (CLDN6 x CD3) in solid tumors.
- Appointed Bart Cornelissen as new CFO; expects cash runway into 2027.

## SEC filing metadata
- accession: 0001326732-24-000030
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/xncr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000030
- JSON: https://secwatch.observer/filing/0001326732-24-000030.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000030.txt

## Key facts
- Earnings Releases
  Xencor Inc reported the first quarter ended March 31, 2024 results: revenue $12.8 million, net income $68.0 million, or $(1.11) on a fully diluted per share basis, EPS $(1.11) on a fully diluted per share basis.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $12.8 million
  - Net income: $68.0 million, or $(1.11) on a fully diluted per share basis
  - EPS: $(1.11) on a fully diluted per share basis
  - Result: reported results
  source text: marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023. Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023. Total revenues earned in the first quarter of 2024 included non-cash royalty revenue from Xencor’s Alexion and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.